Every Form 4 that Prestige Consumer Healthcare Inc. (PBH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBH filings page.
ZIER DAWN M. reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. reported that director Dawn M. Zier received a grant of 2,981 restricted stock units, calculated as $155,000 divided by the $52.00 closing share price on August 4, 2026, under the director compensation program. The RSUs vest on the first anniversary of grant and will be settled in one share of common stock per unit after vesting upon the earliest of the director’s death, separation, or a change in control, and her directly held common stock position is now 19,514 shares.
Kelly John F. reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare director John F. Kelly received a grant of 2,981 restricted stock units on August 4, 2026, valued at $155,000 using a $52.00 share price under the director compensation program. These RSUs vest on the first anniversary of grant and are settled in common stock upon the earliest of his death, separation, or a change in control, after which his reported direct holdings total 7,832 shares.
DArecca James reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. director James DArecca received a grant of 2,981 restricted stock units, valued at $155,000 based on a $52.00 share price, under the director compensation program. The units vest after one year and will be settled in common stock upon specified separation, death, or change-in-control events, bringing his reported holdings to 9,572 shares.
Prestige Consumer Healthcare Inc. reported that director Celeste A. Clark acquired an equity award of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing share price on August 4, 2026, under the director compensation program. The units vest on the first anniversary of grant and will be settled in one share of common stock per vested unit upon the earliest of Clark’s death, separation, or a change in control. Following this award, 16,511 shares of common stock are reported as directly owned.
BYOM JOHN E reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. director John E. Byom received a grant of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing price on August 4, 2026, under the director compensation program. The RSUs vest after one year, and his direct common stock holdings are now 54,575 shares.
Prestige Consumer Healthcare Inc. executive Christine Sacco, the company’s CFO and COO, reported a tax-withholding disposition of 1,091 shares of common stock at a price of $55.09 per share. This adjustment reflects a correction to an earlier inadvertent error and leaves her holding 57,374 shares directly.
Prestige Consumer Healthcare Inc. Senior VP Operations Jeffrey Zerillo reported an open-market sale of 351 shares of common stock on May 11, 2026 at $52.28 per share. After this transaction, he directly owns 41,810 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Senior VP of Operations Jeffrey Zerillo reported an open-market sale of 305 shares of common stock at $54.36 per share. A separate transaction shows 351 shares withheld at $54.59 per share to cover tax obligations, a non-market event.
After these transactions, Zerillo directly holds 42,161 shares of Prestige Consumer Healthcare common stock, indicating that the reported sale represents only a small portion of his remaining stake.
Prestige Consumer Healthcare CFO & COO Christine Sacco reported a routine tax-related share disposition. On May 7, 991 shares of common stock were withheld at $54.59 per share to cover tax obligations, a non-market transaction. After this, she directly owns 71,636 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. Chief Executive Officer Ronald M. Lombardi reported a routine share withholding for taxes. On May 7, 2026, 2,543 shares of common stock were disposed of at $54.59 per share as a tax-withholding disposition, rather than an open-market sale. Following this transaction, Lombardi directly holds 373,465 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare EVP Mekhail Adel reported a routine tax-related share disposition. On May 7, 2026, 487 shares of common stock were withheld at $54.59 per share to cover tax obligations. After this transaction, Adel directly holds 25,703 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Senior VP Operations Jeffrey Zerillo reported an open-market sale of 1,207 shares of common stock at $54.99 per share. In a separate transaction, 307 shares were disposed of to satisfy tax withholding obligations at $55.75 per share. Following these transactions, he directly holds 44,027 shares after the tax-withholding disposition and 42,820 shares after the open-market sale, indicating these trades involved a relatively small portion of his reported direct holdings.
Prestige Consumer Healthcare CFO & COO Christine Sacco reported a tax-related share disposition. On May 5, 2026, 1,267 shares of common stock were withheld at $55.75 per share to cover tax obligations. After this non‑market transaction, she directly owned 72,627 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. Chief Executive Officer Ronald M. Lombardi reported a routine tax-related share disposition. On the reported date, 2,197 shares of common stock were delivered at $55.75 per share to satisfy a tax liability. Following this tax-withholding disposition, he directly holds 376,008 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. reported that CFO & COO Christine Sacco received equity compensation and related tax withholding transactions in company stock. She acquired 11,976 shares of common stock upon settlement of performance stock units granted on May 5, 2023, which vested on May 4, 2026 based on per share growth goals. She also received a 7,008‑share restricted stock award that vests in three equal installments of 3,992 shares on May 4, 2027, May 4, 2028 and May 4, 2029. To cover tax obligations, 3,434 shares were withheld at $55.31 per share. After these transactions, she directly holds 61,918 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare executive William P’Pool reported equity compensation awards and related tax withholding in common stock. On May 4, 2026, 4,187 shares settled from previously granted performance stock units based on per share growth goals, and 3,675 Restricted Stock Units were awarded at no cost. To cover tax obligations, 1,888 shares were withheld at $55.31 per share. After these transactions, P’Pool directly holds 28,149 common shares, and 100 additional shares are held indirectly in the P’Pool Family Giving Fund.
Prestige Consumer Healthcare Senior VP of Operations Jeffrey Zerillo reported routine equity compensation activity and a small share sale. He received stock awards of 2,857 and 2,450 common shares at no cost, reflecting PSU settlement and RSU grants. To cover tax obligations, 1,243 shares were disposed of, and he later sold 346 shares in an open-market transaction at about $55.32 per share. After these transactions, he directly holds 44,334 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare EVP of Marketing & Sales Adel Mekhail reported equity compensation activity. On May 4, 2026, he acquired 4,014 shares of common stock through settlement of performance stock units that vested based on per share growth goals, and received 3,505 shares of restricted stock.
The company withheld 1,695 shares at $55.31 per share to cover tax obligations, a non‑market disposition. Following these transactions, Mekhail directly owns 26,190 common shares. The restricted stock is scheduled to vest in three equal installments of 1,338 shares on May 4, 2027, May 4, 2028 and May 4, 2029.
Prestige Consumer Healthcare Inc. reported equity compensation changes for Chief Executive Officer Ronald M. Lombardi. He acquired 19,662 shares of common stock on settlement of performance stock units that vested on May 4, 2026 based on per share growth goals, and received a separate grant of 31,468 Restricted Stock Units.
To cover tax obligations, 16,789 shares were disposed of at $55.31 per share through a tax-withholding mechanism rather than an open-market sale. Following these transactions, Lombardi directly holds 358,543 shares of Prestige Consumer Healthcare common stock. The new Restricted Stock Units vest in three equal installments of 6,554 shares in 2027, 2028 and 2029.
Prestige Consumer Healthcare Inc. executive Christine Sacco, the company’s CFO & COO, reported a tax-related share disposition. She had 1,091 shares of common stock withheld at $55.09 per share to cover tax obligations, a non-market transaction. After this withholding, she directly holds 58,344 common shares.
Prestige Consumer Healthcare Inc. insider Jeffrey Zerillo, Senior VP Operations, reported a tax-related share disposition. On May 2, 2026, 432 shares of common stock were withheld at $55.09 per share to cover tax obligations. Following this non-market transaction, he directly holds 40,616 shares.
Prestige Consumer Healthcare Inc. Chief Executive Officer Ronald M. Lombardi reported a routine tax-related share disposition. On May 2, 2026, 2,665 shares of common stock were withheld at $55.09 per share to cover tax obligations, a non‑market transaction. Following this event, Lombardi directly holds 343,864 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare EVP Adel Mekhail reported a compensation-related share withholding. On this Form 4, 542 shares of common stock were disposed of at $55.09 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. Following this transaction, Mekhail directly holds 20,366 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. officer William P’Pool reported routine share movements involving company common stock. On May 2, 2026, 599 shares were disposed of at $55.09 per share as a tax-withholding disposition to cover obligations, not as an open-market sale. After this transaction, P’Pool held 22,175 shares directly. A separate indirect entry shows 100 shares held in the P’Pool Family Giving Fund via Fidelity Charitable, reflecting a charitable-related position rather than personal trading.
Prestige Consumer Healthcare Inc. Senior VP of Operations Jeffrey Zerillo reported an open-market sale of common stock. On February 11, 2026, he sold 1,000 shares of Prestige Consumer common stock at $65.93 per share. After this transaction, he directly owned 41,048 shares of the company’s common stock.
Prestige Consumer Healthcare senior vice president Jose Luis Rosado reported receiving 3,426 shares of common stock on January 6, 2026, at a price of $0 per share, bringing his direct holdings to 3,436 shares.
The award represents restricted stock units that are scheduled to fully vest on January 6, 2030, indicating a long-term, equity-based component to his compensation aligned with the company’s future performance.
Prestige Consumer Healthcare Inc. officer Jeffrey Zerillo, Senior VP Operations, reported two open-market sales of company stock. On 11/28/2025, he sold 719 shares of common stock at $60 per share, leaving him with 42,329 shares beneficially owned afterward. On 12/01/2025, he sold an additional 281 shares at $60 per share, reducing his holdings to 42,048 shares.
The filing is a Form 4, which discloses changes in ownership by company insiders and confirms that Zerillo’s holdings remain directly owned after these transactions.
Prestige Consumer Healthcare Inc. (PBH) director John E. Byom reported a sale of company stock. On 11/25/2025, he sold 3,000 shares of common stock at a price of $59.35 per share in a single reported transaction where multiple lots at the same price were combined. After this sale, he beneficially owns 51,594 shares, held directly. The filing is made on Form 4, which reports changes in the ownership of company equity by an insider who serves as a director.